Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Spotlight on Molecular Profiling

In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation

Ogechi N. Ikediobi, Mark Reimers, Steffen Durinck, Paul E. Blower, Andrew P. Futreal, Michael R. Stratton and John N. Weinstein
Ogechi N. Ikediobi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Reimers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffen Durinck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul E. Blower
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew P. Futreal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Stratton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John N. Weinstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-07-2308 Published June 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. We previously sequenced 24 cancer genes in those cell lines. Eleven of the genes were found to be mutated in three or more of the lines. Using a pharmacogenomic approach, we analyzed the relationship between drug activity and mutations in those 11 genes (APC, RB1, KRAS, NRAS, BRAF, PIK3CA, PTEN, STK11, MADH4, TP53, and CDKN2A). That analysis identified an association between mutation in BRAF and the antiproliferative potential of phenothiazine compounds. Phenothiazines have been used as antipsychotics and as adjunct antiemetics during cancer chemotherapy and more recently have been reported to have anticancer properties. However, to date, the anticancer mechanism of action of phenothiazines has not been elucidated. To follow up on the initial pharmacologic observations in the NCI-60 screen, we did pharmacologic experiments on 11 of the NCI-60 cell lines and, prospectively, on an additional 24 lines. The studies provide evidence that BRAF mutation (codon 600) in melanoma as opposed to RAS mutation is predictive of an increase in sensitivity to phenothiazines as determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay (Wilcoxon P = 0.007). That pattern of increased sensitivity to phenothiazines based on the presence of codon 600 BRAF mutation may be unique to melanomas, as we do not observe it in a panel of colorectal cancers. The findings reported here have potential implications for the use of phenothiazines in the treatment of V600E BRAF mutant melanoma. [Mol Cancer Ther 2008;7(6):1337–46]

Keywords:
  • melanoma
  • BRAF
  • mutation
  • phenothiazine
  • NCI-60
  • cell line
  • cancer
  • V600E
  • chemotherapy
  • trifluoperazine
  • drug screen
  • single nucleotide polymorphism
  • sequencing

Footnotes

  • ↵6 http://www.sanger.ac.uk/genetics/CGP/Census

  • ↵7 http://dtp.nci.nih.gov/docs/cancer/cancer_data.html

  • ↵8 http://www.r-project.org

  • ↵9 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • ↵10 http://www.sanger.ac.uk/CGP/COSMIC

  • Grant support: Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and Wellcome Trust.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted April 18, 2008.
    • Received February 1, 2008.
    • Revision received April 15, 2008.
  • American Association for Cancer Research
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (6)
June 2008
Volume 7, Issue 6
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation
Ogechi N. Ikediobi, Mark Reimers, Steffen Durinck, Paul E. Blower, Andrew P. Futreal, Michael R. Stratton and John N. Weinstein
Mol Cancer Ther June 1 2008 (7) (6) 1337-1346; DOI: 10.1158/1535-7163.MCT-07-2308

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation
Ogechi N. Ikediobi, Mark Reimers, Steffen Durinck, Paul E. Blower, Andrew P. Futreal, Michael R. Stratton and John N. Weinstein
Mol Cancer Ther June 1 2008 (7) (6) 1337-1346; DOI: 10.1158/1535-7163.MCT-07-2308
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • NCI-60 miRNA Analysis
  • Expression Profiling of FdUMP[10] and Top1 Poisons
  • Agilent mRNA and microRNA Profiling in NCI-60
Show more Spotlight on Molecular Profiling
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement